What is Prolocor?
Prolocor is at the forefront of precision diagnostics within cardiovascular health. The company is developing an innovative diagnostic tool designed to assess and manage the risk associated with cardiovascular disease. By quantifying FcyRIIa on the surface of platelets, Prolocor addresses a critical unmet need for individualized therapy in patients with cardiovascular conditions. This technology aims to equip physicians with enhanced information for more informed treatment decisions, positioning Prolocor as a key player in the evolving landscape of personalized medicine.
How much funding has Prolocor raised?
Prolocor has raised a total of $4.9M across 2 funding rounds:
Angel/Seed
$3.2M
Debt
$1.7M
Angel/Seed (2022): $3.2M with participation from Green Park & Golf Ventures and Labcorp
Debt (2024): $1.7M led by Green Park & Golf Ventures and Labcorp
Key Investors in Prolocor
Green Park & Golf Ventures
Green Park & Golf Ventures is a Dallas-based venture capital firm with extensive experience, specializing in investment opportunities within medical-related start-ups. They focus on providing strategic solutions and financial backing to innovative companies.
Labcorp
Labcorp Holdings Inc. is a leading laboratory services company that provides vital information for healthcare decisions. They offer a wide range of diagnostic and biopharma services, supporting pharmaceutical companies, researchers, and healthcare providers.
What's next for Prolocor?
The recent major enterprise-level funding indicates Prolocor is poised for significant scaling and market penetration. This strategic investment will likely fuel further research and development, clinical validation, and commercialization efforts. The company's focus on a critical area of healthcare suggests a trajectory towards establishing its diagnostic tool as a standard in cardiovascular risk assessment, potentially leading to broader adoption and partnerships within the healthcare ecosystem.
See full Prolocor company page
